SOMERSET, N.J.--(BUSINESS WIRE)--Catalent Pharma Solutions, one of the leading advanced drug delivery technology providers to the pharmaceutical industry, announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Metozolv™ ODT (orally disintegrating tablets) metoclopramide HCL utilizing Catalent’s Zydis® fast dissolve technology. Metozolv™ ODT was developed by Wilmington Pharmaceuticals and licensed to Salix Pharmaceuticals. Metozolv™ ODT is the first orally disintegrating tablet formulation for both acute and recurrent diabetic gastroparesis and for the treatment of short-term therapy (4-12 weeks) for adults with symptomatic documented gastroesophageal reflux disease (GERD) who fail to respond to conventional therapy.
